Sessions

The presentation will describe how the World Health Organization Region Europe (WHO EURO) came to select Sweden as its Demo Platform, and South Lapland and the Centre for Rural Medicine as the demo site for showing good practice of how to ensure access to health in remote areas with digital health tools, why Business Sweden initiated this collaboration with WHO, what the Demo Platform entails and how the next planned steps are strategic to Swedish digital health industry internationalisation.

Presentation of the Regional digital health action plan for the WHO European Region 2023–2030.

Within Nordic cooperation and with funding from the Nordic Council of Ministers, a number of projects are underway as part of the Nordic Vision 2030 goals; The Nordic region will become the most sustainable and integrated region in the world. Some examples of ongoing and completed projects are presented during this session. Integrated Healthcare and care (iHAC) 2021-2024 is run by the Centre for Rural Medicine in Storuman Sweden and the Nordic Welfare centre. The project focuses on the citizen perspective in national and regional models for integrated management of healthcare and social care including the data management. Nordforsk runs the more research-oriented project Nordic Commons with a focus on secondary use of health data for research. Nordic Innovation has additional investments related to health data promotion from an innovation perspective.THL in Finland runs the Finnish presidency project 2021-2023, World's Smoothest Cross-Border Mobility and Daily Life Through Digitalisation with a focus on e-prescriptions and Patient Summary. In 2021, the project published the report Baseline study of cross-border data exchange in the Nordic and Baltic countries. The project is partly a continuation of the project the Swedish E-health authority carried out in the Nordic project Care and care at a distance (VOPD) 2018-2021 with a focus on cross border e-prescriptions and patient summaries.This session can be seen as a brief introduction related to what happens within the Nordic Cooperation related to health data.

Nursing practice is transforming at pace to lead improvements in patient outcomes in hospital, primary and community practice. New opportunities are emerging in advanced nursing practice which is a new level of practice defined by knowledge and skills acquisition. There are 4 leadership domains of advanced clinical practice: clinical, professional, health system and health policy leadership. A key component of health systems leadership is driving system change through digital transformation and clinical informatics. The approach to developing advanced clinical practice in east London will be described. Embedded in our approach is the systematic use of our multidisciplinary ‘WeConnect’ digital transformation programme. To implement change and training, a thorough clinical and technical understanding are both needed. This is where the role of the nursing and medical informaticists alongside innovative and engaging advanced clinical practitioners is essential. Key skills for advanced clinical practitioners are the development of autonomous clinical practice based on a foundation of digital skills. These include: use of SNOMED-CT for problem and procedure listing and decision support, analytics and risk based assessments derived from the real world data recorded in the electronic health record. Supporting the journey towards higher levels of digital and SNOMED-CT maturity is a key organisational objective.

In order to improve the conditions for clinical research in Europe and to stimulate multinational clinical trials, CTIS - clinical trial information system - has been developed. It is a platform that is ONE single entrance to the clinical trial application and includes both the drug application and ethical approval. Several years of preparatory work and a one-year transition period have ended and from February 1, 2023 CTIS has been put into use and is mandatory to use. CTIS has been built and improved in close cooperation with users (industry and academia) and national pharmaceutical authorities and EMA, the European Medicines Agency.